Get the Stockscreener App
4.80
0.00%
0.00
After Hours:
4.85
0.05
+1.04%
Passage Bio Inc stock is traded at $4.80, with a volume of 8,690.
It is up +0.00% in the last 24 hours and down -0.62% over the past month.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
See More
Previous Close:
$4.80
Open:
$4.78
24h Volume:
8,690
Relative Volume:
0.15
Market Cap:
$15.45M
Revenue:
-
Net Income/Loss:
$-37.68M
P/E Ratio:
-0.4055
EPS:
-11.8364
Net Cash Flow:
$-30.65M
1W Performance:
+1.05%
1M Performance:
-0.62%
6M Performance:
-32.35%
1Y Performance:
-37.50%
1-Day Range:
$4.61
$4.85
1-Week Range:
$4.61
$5.05
52-Week Range:
$3.29
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.80 | 15.45M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-21-26 | Downgrade | TD Cowen | Buy → Hold |
| Apr-21-26 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-31-26 | Initiated | Oppenheimer | Outperform |
| Feb-10-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Passage Bio stock gains 1.01 percent as Remix deal advances - ad-hoc-news.de
Fierce Biotech Layoff Tracker 2026: Novo reveals 4k more employees were laid off; Sionna halves staff - Fierce Biotech
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
688187.SH PE Ratio & Valuation, Is 688187.SH Overvalued - Intellectia AI
Passage Bio stock holds steady as investors eye recent trial and cash runway - ad-hoc-news.de
Passage Bio stock holds near the 52-week low - ad-hoc-news.de
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Stocktwits
PASG Q2 2026 Earnings: Narrower Than Expected Loss of $2.44 Per Share Lifts StockNet Profit Margin - dars.gov.et
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
Passage Bio stock holds steady as investors weigh gene therapy pipeline and recent losses - ad-hoc-news.de
Passage Bio Amends Remix Merger, Private Financing Terms - TipRanks
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE - TradingView
Remix deal would leave Passage Bio (NASDAQ: PASG) investors a small slice of the combined company - Stock Titan
PASG Q2 2026 Earnings: Loss Narrows on Consensus Beat, Shares Edge Up 3.04%Tangible Book Value - dars.gov.et
Passage Bio stock reacts to reverse split as investors watch next steps - ad-hoc-news.de
PASG Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 4.39%Analyst Consensus Shift - dars.gov.et
Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateTech Earnings Analysis - vinanet.vn
Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move - dars.gov.et
GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity - openPR.com
Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan
Passage Bio | SCHEDULE 13G/A: Others - Moomoo
PASG Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2% Share GainSpecial Dividend Alert - vinanet.vn
Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView
PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView
Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan
Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CYBR.O Forecast — Price Prediction for 2026. Should I Buy CYBR.O? - Intellectia AI
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
Post Holdings (POST) Slips 1.25% as Shares Test Key Support ZoneWatchlist Stock Ideas - careplusvn.com
REPX Q1 2026 Earnings: Deep EPS Miss Delivers -369.75% Surprise as Shares Gain 2.24%Revenue Breakdown Analysis - vinanet.vn
PASG Q2'26 Earnings: EPS estimate is (2.65) USD - TradingView
Passage Bio Inc. (PASG) Slips 3% as Shares Approach Key Support LevelIV Rank - careplusvn.com
Passage Bio Inc (PASG) Cash Flow - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - tradingkey.com
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Balance Sheet - TradingKey
PASG|Passage Bio Inc|Price:4.570|Chg%:-0.370 - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG - TradingView
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):